107 results
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
, will be one of three host-directed investigational drugs assessed in this study, with the safety and efficacy of each investigational drug … the safety and effectiveness of using GOHIBIC to treat people in the hospital with COVID-19. Please see additional information in the Fact Sheet
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
design in moderate-to-severe CSU and HS, with study initiation expected by the calendar year-end of 2024 and a goal of generating additional safety … will be assessed via weekly visits to evaluate safety, PK and preliminary signs of efficacy. After the 4-week treatment period, patients will be followed
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
achieve a clinical edge and prove to be a differentiated competitor INF904 is an oral drug with no known safety concerns related to the MoA … with “best in class” potential Favorable drug safety profile supported by preclinical studies and data reported from InflaRx’s Phase I SAD and MAD trials
6-K
EX-99.1
IFRX
InflaRx N.V.
21 May 24
Report of Foreign Private Issuer
4:15pm
or baricitinib. All patients received standard of care. Safety was also assessed.
The point estimate for 28-day all-cause mortality was 6.3% in the vilobelimab … =0.006), a significant relative reduction.
The co-administration of vilobelimab with baricitinib or tocilizumab was not associated with safety
6-K
EX-99.2
ku7 9hpktjzzl8k1i4z
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.3
vy84r
8 May 24
Report of Foreign Private Issuer
8:43am
6-K
EX-99.1
lk9qsrfs
21 Mar 24
Corporate Presentation March 2024
5:00pm
6-K
EX-99.1
fdmd4 lrq0i8u
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
6-K
EX-99.1
l73 x2x84b65
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
EX-99.1
cysqhsi 5b
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.2
mywrs e2pep8mtc
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.1
kctj9 w866ba13
6 Nov 23
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
8:00am
6-K
EX-99.2
927mx9
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.3
6b3wm
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.1
x754z8a1jtipr
11 Sep 23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
8:45am
6-K
EX-99.2
yytitugtb62jepx842k
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.3
aud2 leplnf395yfwt4
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
63i7g3vbdlulplkv5byb
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am